| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer
1 company
Robert Eugene Kristal last filed a Form 4 in February 2025, as Chief Financial Officer at BRTX. Robert Eugene Kristal's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Our model assigns Robert Eugene Kristal a below-average insider score of 38/100, based on 3 past trades. Over a 12-month horizon, 66.7% of those trades were profitable, with an average 12-month return of +11.4%.
At the last filing, the largest reported position was 7,994 shares of BRTX. Net of sales, the BRTX filings show accumulation of 7,994 shares.
Robert Eugene Kristal has 8 Form 4 filings on record from November 2021 to February 2025, all as Chief Financial Officer at BioRestorative Therapies (BRTX), 2021–2025.
The 9 reported transactions were 5 option or other derivative awards, 3 open-market purchases and 1 disposition back to the company.
Counted by filing, the open-market trades come to 3 purchases worth about $45K and no sales.
The largest open-market purchase was 7,600 shares of BRTX at an average $5.71 on April 8, 2022, about $43K. Twelve months later BRTX was down 37%.
Shares as reported in the last Form 4 for each company; the most recent is from February 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 15, 2022 | BRTX Biorestorative Therapies, Inc. | Chief Financial Officer | Buy | 194 | $3.61 | $700.34 | +2.5% | -13.9% | +55.7% | |
| Jun 7, 2022 | BRTX Biorestorative Therapies, Inc. | Chief Financial Officer | Buy | 200 | $4.56 | $912.00 | +2.6% | -31.1% | +15.2% | |
| Apr 8, 2022 | BRTX Biorestorative Therapies, Inc. | Chief Financial Officer | Buy | 7,600 | $5.71 | $43,396.00 | New | -39.3% | -36.8% |